Legislation expanding pharmacist scope of practice to furnish Human Immunodeficiency Virus pre-exposure prophylaxis: A content analysis

被引:3
作者
Cocohoba, Jennifer [1 ,3 ]
Tweedie, Lauren [1 ]
Frank, Michael [1 ]
Mcelya, Brad [2 ]
Witt, Ed [2 ]
机构
[1] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA USA
[2] Walgreen Co, Deerfield, IL USA
[3] 521 Parnassus Ave, Box 0622, San Francisco, CA 94143 USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2024年 / 7卷 / 01期
关键词
HIV; legislation; pharmacist; pre-exposure prophylaxis;
D O I
10.1002/jac5.1906
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Approximately 1.2 million persons in the United States have indications for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) yet utilization remains low. Alternative models for PrEP access, such as community pharmacy programs where pharmacists may prescribe and dispense HIV PrEP medications, may help improve rates of utilization. Individual states have begun to pass laws governing expanded pharmacist practice for provision of PrEP.Methods: An internet search was conducted from January 2022 to June 2023 to identify United States legislative bills which support the independent provision of PrEP by pharmacists. A content analysis was conducted of the bill text to conceptualize key components, compare these across states, and hypothesize implications for implementation and pharmacy practice.Results: Twelve states (Arkansas, California, Colorado, Nevada, Utah, New Mexico, Virginia, Oregon, Illinois, Maine, Rhode Island, and Connecticut) with legislation supporting pharmacist-furnished HIV PrEP were identified. Content analysis revealed differences in required pharmacist training, conditions for furnishing PrEP, total amount of PrEP permitted for dispensing, and discussions of pharmacist-provided laboratory testing and reimbursement.Conclusion: Pharmacist-furnished PrEP is rapidly gaining support as a means to expand access to HIV prevention tools. State-to-state differences in legislation will have an impact on implementation and scalability of these models. It will be important to observe states that were early adopters of this type of legislation and who experienced challenges in implementing such programs in order to refine the new legislation being presented in other states.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 24 条
[1]  
[Anonymous], HB2958 2021 REGULAR
[2]  
[Anonymous], WHITE HOUSE NATL HIV
[3]  
[Anonymous], PDF PHARMACIST INITI
[4]  
[Anonymous], HB0178 INTERNET CITE
[5]  
[Anonymous], SB325 TEXT
[6]  
[Anonymous], Bill Text-SB-159 HIV: preexposure and postexposure prophylaxis
[7]  
[Anonymous], LIS BILL TRACKING HB
[8]  
[Anonymous], LegiScan
[9]  
[Anonymous], PREVENT INDICATORS M
[10]  
[Anonymous], 2020, HIV Surveillance Data Tables | Reports | Resource Library | HIV/AIDS | CDC